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Cost effective & timely
Decreasing resources !
RESISTANCE:
• Detection / method-dependant
• Level of in vitro expression
• Predictive value







emergence + spread + escalation
« Difficult to treat » patients
A few years of wonder and then …
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Some of the XXIst century-
Challenges in infectious diseases
 Microorganisms
 Increasing antimicrobial Resistance
 Resistance determinant
 « Pathogens » evolution



















 Salmonella (ESBL, FQ)





Appropriate therapy saves lives
 Early inappropriate therapy
 Increase of mortality in severe infection
 Infection with antibiotic-R bacteria
 Increase of risk of inappropriate therapy
 Antibiotic-R organisms
 More commonly associated with inadequate therapy
 Streamlining therapy to narrow spectrum drug
 Saving costs
Weinstein et al. Clin Infect Dis 1997:24:584
Kollef et al Clin Infect Dis 2000: 31 (suppl. 4): S131
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Appropriate therapy saves lives
 Target empiric therapy to likely
pathogens, 
 based on hospital, regional, specific
epidemiology.
 Target definitive therapy to known
pathogens, 
 based on accurate, quantitative S results
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Main goals of anti-infective
therapy
 Clinical cure of patients
 Eradicating the pathogens
 To avoid development of resistance
 To avoid transmission 
By giving « supposedly » or proven effective antibiotic
Choices often based on results in terms of « S » or 
« Non S »
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SIR, bacteria are not simply
« S » or « Non S »
S
 Varies over a wide range
 May be quantified by MIC
 May result in overdosing or underdosing
 Risk of R development
 Unnecessary costs
 Increase morbidity/mortality
 Standard definition of Resistance
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ACCURATE DETECTION of clinically
& epidemiologically significant
R-determinants
COST-EFFECTIVE to patient care 
& infection control
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Are AST results clinically
relevant & reliable ?
Therapeutic predictive values
 Many variables affecting results
 Standardization
 In vitro // in vivo  ?
 Current breakpoints
 S, I, R
 NCCLS, BSAC, SFM, Japanese, …. 
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Different interpretative criteria
P.aeruginosa ATCC 27853, same MIC yet different categories
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Are AST results clinically
relevant - reliable ?
Therapeutic predictive value
 Many variables affecting results
 Standardization / in vivo  ?
 Current breakpoints
 S, I, R
 NCCLS, BSAC, SFM, Japanese, ….
 Safety or efficacy ?
 Evolution // pharmacology-pharmacodynamics ?
 β-lactams, aminoglycosides, FQ













Practical recommendations for 
PK/PD -optimized therapy
Drug class Recommendations
B-lactams -remain > MIC for at least 50 % of the time
-Fractionate the dose
Aminoglycosides -Obtain Cmax/MIC ratio of at least 8
-Administer once daily
Fluoroquinolones -Obtain a 24-H AUC/MIC ratio > 125
-Obtain Cmax/MIC ratio of at least 8
-Do not overfractionate the daily dose
-Consider lowering breakpoints for older FQ
Etc.
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AST methods routinely used
in Belgium (E.faecium EQC-ISP 2003) 
 « Disk » diffusion
 Paper discs 25 %
 Rosco tablets 50 %
 « MIC » Automated system
 Vitek 1 7.5 %
 Vitek 2 17 %
 Real MIC Etest
 Vancomycin 25 % 
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To prevent antimicrobial R
= to treat infections effectively
 Detection of Resistance
 Target optimal therapy
 Choice of the most potent drug in class
 Giving optimal regimen
 To maximise effect
 To enhance bacterial eradication
 To minimise development of R
 Strategies using PK/PD parameters
Real MIC = one necessary component !!
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Improvement expected for 
clinical microbiology lab.
 Detection of resistance
 Determination of true MICs 
 To be cost effective
 To define clinical circumstances requiring MIC
 To identify organisms requiring MIC
 To define organisms, phenotypes or clinical
circumstances requiring specific method for 









 Cystic fibrosis, other chronic infections, 
sterile site infections 
 Serious nosocomial infections
Versus




 MIC < 0.1 mg/L 
 Penicillin G for 4 weeks
 MIC 0.1-0.5 mg/L
 Penicillin + gentamicin 2 weeks; penicillin 2 
weeks
 MIC > 0.5 mg/L
 Penicillin + gentamicin for 4-6 weeks
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Organisms or type of R to 
detect worthy of Etest MICs
R proned, invasive, virulent
 S.pneumoniae
 N.gonorrhoeae
 Fastidious bacteria : NF GNB, GPB, etc
 Anaerobes
 Opportunist with no defined interpretative criteria
 Yeasts, fungi
 Confirmation / Detection of R
 Penicilline (Pneumo)










































Gram positive Bacilli AST algorithm
Sterile site, pure culture
Multiple positive blood cultures
Bacillus spCorynebacterium sp
Etest
Penicillin
Cefotaxime
Vancomycin
FQ
Etest
Penicillin
Clindamycin
Vancomycin
FQ
